Cell X Technologies
- Company typePrivate
- Founded2023
- HeadquartersCleveland, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Cell X Technologies firmographics
Firmographics- Name
- Cell X Technologies
- Legal name
- Cell X Technologies
- Website
- https://cellxtechnologies.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Cell X Technologies industry classification
Industry- Product category
- Cell Therapy Manufacturing Automation
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG)
- akta.pro secondary industries
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
Keywords
Where Cell X Technologies is headquartered
LocationHeadquarters
- HQ city
- Cleveland
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Cell X Technologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Celligent Platform Licensing and Services: Cell X Technologies generates revenue through licensing its Celligent automation platform and providing associated services for cell therapy manufacturing. The platform supports both autologous and allogeneic cell therapies, as well as tissue engineering and artificial organ applications.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels3 records
Cell X Technologies product offering
Product offeringCore offering
Cell X Technologies sells and licenses the Celligent™ Cell Processing Platform, an integrated system combining proprietary robotics, imaging, and artificial intelligence that automates GMP-compliant manufacturing of autologous and allogeneic cell therapies, stem cell-derived therapies, tissue engineering, and artificial organ applications. The platform delivers automated handling and selection, machine learning-driven process optimization via the CxKnowledge data bank, and 21 CFR Part 11 compliant data collection that supports IND filings.
Product overview
Cell X Technologies offers a single unified product—the Celligent™ platform—which combines robotics, imaging, and artificial intelligence into one integrated cell processing solution. The platform enables scalable, GMP-compliant manufacturing workflows for cell therapies, stem cell-derived therapies, tissue engineering, and artificial organ applications. Key capabilities include BioAdaptive Automation for automated handling and selection, machine learning-driven process optimization via the CxKnowledge data bank, and comprehensive data collection for regulatory filings including IND submissions.
Differentiator
Problem solved
Functional benefit
Products and services
- Celligent™ Cell Processing Platform Integrated robotic, imaging, and AI-driven cell processing platform that automates GMP-compliant manufacturing workflows for cellular therapies, stem cell-derived therapies, tissue engineering, and artificial organ applications; targeted at cell therapy developers and biopharma innovators requiring reproducible, IND-ready cell processing.
Quantifiable outcome
- Reduces operator-dependent variability in iPSC culture and differentiation
- +2 more outcomes
Companies that use Cell X Technologies
Customer profileSegments4 records
Ideal customer profiles3 records
Cell X Technologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature5 records
Cell X Technologies partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- BioLaminacoreCell X Technologies announced a collaboration with BioLamina to integrate BioLamina's defined laminin reagents with Cell X's Celligent automation platform for advanced therapy manufacturing. The partnership aims to reduce operator-dependent variability and enhance reproducibility in iPSC culture and differentiation, targeting scalable, GMP-compliant workflows for next-generation cell therapies. The collaboration combines Cell X's walk-away automation and imaging capabilities with BioLamina's full-length human recombinant laminin-521 and laminin-511 reagents.
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
Cell X Technologies competitors and assessment
Company assessmentDirect peers
- Cellares: Cellares develops the Cell Shuttle, an automated cell therapy manufacturing platform integrating robotics and software for GMP-compliant production. It directly competes with Celligent in the iPSC and cell therapy automation space, targeting the same developer customer base with a similar end-to-end value proposition.
- Ori Biotech: Ori Biotech builds the IRO platform, a closed, automated cell and gene therapy manufacturing system combining hardware, software, and analytics. It is a direct competitor in cell therapy process automation, addressing the same scalability and reproducibility pain points Cell X targets.
- Multiply Labs: Multiply Labs produces robotic manufacturing systems for cell therapies and personalized medicines, including iPSC-derived products. It overlaps with Cell X on robotics-driven cell processing automation and targets a similar cell therapy developer customer base.
Broad incumbents
- Cytiva: Cytiva (a Danaher company) offers a broad portfolio of cell therapy manufacturing tools, automation, and services including the Sefia and Xuri cell expansion systems. As a large incumbent, it competes with Cell X in cell therapy automation while also serving as a potential partner or acquirer.
- Lonza Cell & Gene Technologies: Lonza is a global CDMO and process development leader with significant cell and gene therapy manufacturing automation capabilities. It is a broad incumbent addressing the same customers as Cell X, both as a potential competitor for automation technology and as a partner via CDMO relationships.
- Miltenyi Biotec: Miltenyi Biotec provides cell processing instruments, reagents, and GMP-compliant manufacturing solutions for cell and gene therapy. It overlaps with Cell X on automated cell handling and serves the same therapeutic developer customers, though with a much broader portfolio.
- Thermo Fisher Scientific (Cell Therapy): Thermo Fisher offers cell therapy manufacturing platforms, including the Gibco CTS product line and the Cell Therapy Systems (CTS) DynaMag family. It is a broad incumbent competitor and potential partner addressing GMP-compliant cell processing workflows.
- Sartorius (Cell Analytics & Automation): Sartorius offers bioprocessing and cell analytics automation products used in cell therapy manufacturing, including the Incucyte live-cell imaging platform. It competes with Cell X at the intersection of automated cell processing, imaging, and GMP workflow support.
Emerging players
- bit.bio: bit.bio operates an iPSC cell programming platform (io Cells) with an integrated manufacturing approach combining biology and automation. It intersects with Cell X as both a potential customer (cell therapy developer needing automation) and a competitor in standardized iPSC workflows.
- Stemcell Technologies: Stemcell Technologies provides cell culture media, instruments, and automation tools for cell therapy and regenerative medicine research. It overlaps with Cell X in serving stem cell researchers and developers with workflow automation tooling.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks4 records
Key highlights7 records
Customer concentration
Cell X Technologies social profiles
Digital presenceCell X Technologies compliance and trust
Trust signalCompliance1 record
Cell X Technologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cell X Technologies leadership team
Management profileNumber of profiles
Profiles6 records
Cell X Technologies funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cell X Technologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cell X Technologies
What does Cell X Technologies do?
Cell X Technologies sells and licenses the Celligent™ Cell Processing Platform, an integrated system combining proprietary robotics, imaging, and artificial intelligence that automates GMP-compliant manufacturing of autologous and allogeneic cell therapies, stem cell-derived therapies, tissue engineering, and artificial organ applications. The platform delivers automated handling and selection, machine learning-driven process optimization via the CxKnowledge data bank, and 21 CFR Part 11 compliant data collection that supports IND filings.
Is Cell X Technologies a public or private company?
Cell X Technologies is a private company. It is classified as venture growth investor backed and is currently operating.
When was Cell X Technologies founded?
Cell X Technologies was founded in 2023. It employs 11 to 50 people.
Where is Cell X Technologies based?
Cell X Technologies is headquartered in Cleveland, United States, in the North America region.
How does Cell X Technologies make money?
One revenue line is on record: celligent Platform Licensing and Services.
Who are Cell X Technologies's main competitors?
Direct peers on record are Cellares, Ori Biotech and Multiply Labs. Broad incumbents are Cytiva, Lonza Cell & Gene Technologies, Miltenyi Biotec, Thermo Fisher Scientific (Cell Therapy) and Sartorius (Cell Analytics & Automation). Emerging players are bit.bio and Stemcell Technologies.
Does Cell X Technologies have an API?
No public API is recorded for Cell X Technologies.
What industry is Cell X Technologies in?
Cell X Technologies's product category is Cell Therapy Manufacturing Automation. Its primary akta.pro industry code is HLAAABAG, Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish), with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 334516 and its SIC code is 3826.